BioVinc LLC (BV) has discovered a novel skeletal selective therapy for life threatening orthopedic infections and osteomyelitis. BV has demonstrated its product OsteoFloxacin™ is the only antibiotic known to kill the deadly methicillin-resistant Staphylococcus aureus (MRSA) within mature bone biofilms.1 Thus eradication in currently incurable MRSA infected implants, which often leads to amputation and death, is now possible. In addition, treatment costs per patient will be reduced by avoiding lengthy hospitalizations, serious complications, and readmissions. The company is now positioned to complete regulatory studies and initiate Phase 1 clinical trials in less than two years. BioVinc is seeking a milestone driven investment to secure first in human studies for OsteoFloxacin™. A detailed plan and milestones are available upon request.
MARKET Potential: OsteoFloxacin™ as an intermittent IV dose for bone and artificial joint related infections, which are major market opportunities worldwide, has an estimated market of over $1.7 billion/yr. Current treatments call for extended use (6-12 weeks) of IV antibiotics, which are at best marginally effective, and healthcare costs that average >$100,000/patient. OsteoFloxacin™ in combination with a novel biomarker advanced by our team will allow our customers, orthopedic surgeons, to have vision, like never before, into the resolution of deep bone infections. Providers will have a very strong incentive to adopt this drug which we envision can also be sold in combination with orthopaedic implants. This indication allows orphan drug status with the FDA providing extended market exclusivity. By partnering with a device maker, Osteofloxacin™ may be positioned as the gold standard in all implant-associated bone infections as an ultimate commercial pathway.
Contact:
Dr. Shuting Sun, CEO, shuting.sun@biovinc.com;
Dr. Frank E. Ebetino, CSO/President, halebetino@biovinc.com
Reference:
- Ren Y, Weeks J, Xue T, Rainbolt J, de Mesy Bentley KL, Shu Y, et al. Evidence of bisphosphonate-conjugated sitafloxacin eradication of established methicillin-resistant S. aureus infection with osseointegration in murine models of implant-associated osteomyelitis. Bone Res. 2023;11(1):51.